Victory Capital Management
ARCT icon

Victory Capital Management’s Arcturus Therapeutics ARCT Stock Holding History

Victory Capital Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-23,970
Closed -$612K – 2540
2023
Q3 		$612K Sell
23,970
-710
-3% -$21.9K ﹤0.01% 1894
2023
Q2 		$708K Buy
+24,680
New +$672K ﹤0.01% 1832
2021
Q2 		– Sell
-4,942
Closed -$204K – 2744
2021
Q1 		$204K Buy
+4,942
New +$295K ﹤0.01% 2521

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Victory Capital Management's ARCT Position: Q4 2023 in Review

Victory Capital Management sold out of Arcturus Therapeutics (ARCT) in Q4 2023, closing a stake of 23,970 shares — an estimated $612K sold.

Victory Capital Management first reported a position in ARCT in Q1 2021 and held it in 3 quarters. The position peaked at $708K in Q2 2023. 165 funds tracked by Wall St. Rank hold ARCT as of Q4 2023.

  • Victory Capital Management reported no remaining Arcturus Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Victory Capital Management sold 23,970 Arcturus Therapeutics shares in Q4 2023, an estimated $612K.
  • Victory Capital Management first reported a position in Arcturus Therapeutics in Q1 2021 and held it in 3 quarters.
  • Victory Capital Management's Arcturus Therapeutics position peaked at $708K in Q2 2023.
  • 165 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2023.

Based on Victory Capital Management's 13F filing for Q4 2023, filed 5 Feb 2024.